COVID-19 Vaccine Results A Breakthrough Moment For BioNTech

Founder Considers Its Focus To Be Immunotherapy, Not mRNA

 
• By Andrew McConaghie

Approval for the first-to-market COVID-19 vaccine would transform BioNTech – but major challenges in meeting global demand and for its oncology pipeline await.

Stafford / United Kingdom - November 9 2020: Pfizer BioNTech Covid-19 vaccine concept. Syringe balanced on a fingertip and blurred company logos on the background. Selective focus.
BNT162b1 may become known as the 'Pfizer vaccine' but BioNTech will be transformed by its likely success.

More from Business

More from Scrip